Screener
Integra LifeSciences IART Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of borrowings under securitization facility | — | 87,800 |
| Current portion of lease liability - operating leases | 13,920 | 14,019 |
| Accounts payable, trade | 82,637 | 95,726 |
| Contract liabilities | 11,699 | 11,463 |
| Income tax payable | 3,236 | 3,651 |
| Accrued compensation | 68,177 | 74,079 |
| Accrued expenses and other current liabilities | 107,618 | 130,493 |
| Total current liabilities | 330,881 | 455,981 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's deferred revenue?
- Integra LifeSciences (IART) reported deferred revenue of $11.7M in Q2 2026.
- How has Integra LifeSciences's deferred revenue changed year-over-year?
- Integra LifeSciences's deferred revenue increased by 5.4% year-over-year, from $11.1M to $11.7M.
- What is the long-term trend for Integra LifeSciences's deferred revenue?
- Over 5 years (2020 to 2025), Integra LifeSciences's deferred revenue has grown at a 16.8% compound annual growth rate (CAGR), from $5.28M to $11.46M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Integra LifeSciences's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude